This page shows the latest MEDI1814 news and features for those working in and with pharma, biotech and healthcare.
compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly and AZ will collaborate on the development of MEDI1814, an antibody against amyloid-beta 42 (Aβ42), which is currently in phase I trials. ... MEDI1814 dose-dependently reduces levels of the Aβ42 peptide - which is thought to be particularly
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...